What is the RSV Vaccine?

The RSV (Respiratory Syncytial Virus) vaccine is designed to protect against a common virus that can cause serious respiratory illness, particularly in:

  • Older adults (especially those over 60)
  • Infants and young children
  • People with weakened immune systems or chronic health conditions

The RSV vaccine helps reduce the risk of hospitalisation and complications from RSV infection.

 

What is Guillain-Barré Syndrome (GBS)?

Guillain-Barré Syndrome (GBS) is a rare condition where the body’s immune system attacks the nerves. It can cause:

  • Muscle weakness
  • Tingling sensations
  • Difficulty walking
  • In severe cases, paralysis

Most people recover from GBS, though recovery can take weeks or months. Very rarely, it can be life-threatening.

 

Is There a Risk of GBS from the RSV Vaccine?

  • In very rare cases, some vaccines have been linked to GBS, including vaccines for influenza and other infections.
  • Clinical trials and post-marketing safety monitoring have identified a possible small increased risk of GBS after the RSV vaccine, particularly in older adults.
  • The estimated risk is extremely low—approximately 1–2 cases per 100,000 people vaccinated, though this may vary by population.

What Are the Symptoms of GBS to Watch For?

Seek medical help immediately if you experience any of the following symptoms after RSV vaccination:

  • Weakness or tingling in the legs or arms
  • Difficulty walking or moving
  • Trouble breathing or swallowing
  • Rapid onset of muscle weakness

These symptoms typically begin within a few days to a few weeks after vaccination if GBS is going to occur.

 

Who Should Be Cautious?

Tell your healthcare provider before getting the RSV vaccine if you:

  • Have ever had GBS before
  • Have any ongoing neurological disorders
  • Are concerned about vaccine safety

 

Balancing Risks and Benefits

While the potential risk of GBS exists, it is very rare. RSV infection can be serious, especially in older adults or those with chronic health conditions. For most people, the benefits of RSV vaccination outweigh the risks.

 

Reference:     https://www.gov.uk/drug-safety-update/abrysvov-pfizer-rsv-vaccine-and-arexvyv-gsk-rsv-vaccine-be-alert-to-a-small-risk-of-guillain-barre-syndrome-following-vaccination-in-older-adults#advice-for-healthcare-professionals-to-provide-to-patients